Tag: SEC v. Panuwat
Professor Coffee tackles the “shadow trading” theory
Here is a great article—no surprise considering its author, Columbia Law Professor John Coffee—that practically gives the last rites to the “shadow trading” theory recently accepted by a federal district court (see this PubCo post) and a jury (see this PubCo post) in SEC v. Panuwat. If, that is, the theory ever reaches the Supreme Court. In Panuwat, the jury in a federal district court in California determined that Matthew Panuwat was civilly liable for insider trading on a set of highly unusual facts under the misappropriation theory—misappropriation of confidential information used to trade in securities in breach of a duty to the source of the information. According to Coffee, prior to Panuwat, cases involving the misappropriation theory “seem to have involved conduct by the defendant that caused ‘likely harm’ to the shareholders of the source of the information.” But not so in Panuwat. Rather than a fiduciary obligation, he suggests, perhaps the duty that Panuwat breached was really a contractual duty owed to his employer? And, in that case, should the SEC be the party enforcing it? His arguments may be highly controversial—certainly the SEC would disagree—but thought-provoking nonetheless and definitely worth a read.
The jury finds shadow trading is a thing
The trial took eight days. The jury took two hours. On Friday, in the case of SEC v. Panuwat, the jury in a federal district court in California determined that Matthew Panuwat was civilly liable for insider trading under the misappropriation theory. This case dates back to August 2021, when the SEC filed a complaint in the U.S. District Court charging Panuwat, a former employee of Medivation Inc., an oncology-focused biopharma, with insider trading in advance of Medivation’s announcement that it would be acquired by a big pharma company, Pfizer. As you know by now, this case has often been viewed as highly unusual: Panuwat didn’t trade in shares of Medivation or shares of the acquiror, nor did he tip anyone about the transaction. No, the SEC’s novel—but winning—theory of the case was that Panuwat engaged in “shadow trading,” using the information about the acquisition of his employer to purchase call options on Incyte Corporation, another biopharma that the SEC claimed was comparable to Medivation, based on an assumption that the acquisition of Medivation at a healthy premium would probably boost the share price of Incyte. Panuwat made over $120,000 in profit. According to a statement from the Director of the SEC’s Division of Enforcement, Gurbir S. Grewal, “[a]s we’ve said all along, there was nothing novel about this matter, and the jury agreed: this was insider trading, pure and simple. Defendant used highly confidential information about an impending announcement of the acquisition of biopharmaceutical company Medivation, Inc., the company where he worked, by Pfizer Inc. to trade ahead of the news for his own enrichment. Rather than buying the securities of Medivation, however, Panuwat used his employer’s confidential information to acquire a large stake in call options of another comparable public company, Incyte Corporation, whose share price increased materially on the important news.”
You must be logged in to post a comment.